Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael M Kitt

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Antimicrobial Agents and Chemotherapy|June 3, 2010
Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteersJeng-Pyng Shaw, Jonathan Cheong, Michael R Goldberg, et al.
Autonomic Neuroscience : Basic & Clinical|August 17, 2021
The discovery and development of gefapixantAnthony P Ford, Michael P Dillon, Michael M Kitt, et al.
The Journal of Antimicrobial Chemotherapy|July 1, 2008
Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjectsShekman L Wong, Steven L Barriere, Michael M Kitt, et al.
Diagnostic Microbiology and Infectious Disease|September 18, 2010
In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studiesKevin M Krause, Steven L Barriere, Michael M Kitt, et al.
Pharmacotherapy|December 25, 2009
Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancinMichael R Goldberg, Shekman L Wong, Jeng-Pyng Shaw, et al.
Pharmacotherapy|July 27, 2010
Single-dose pharmacokinetics and tolerability of telavancin in elderly men and womenMichael R Goldberg, Shekman L Wong, Jeng-Pyng Shaw, et al.
Pharmacotherapy|January 27, 2010
Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjectsShekman L Wong, Michael R Goldberg, Charles H Ballow, et al.
Journal of Clinical Pharmacology|May 16, 2009
Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participantsShekman L Wong, Fritz Sörgel, Martina Kinzig, et al.
American Journal of Surgery|December 20, 2008
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical proceduresSamuel E Wilson, William O'Riordan, Alan Hopkins, et al.
Pulmonary Therapy|August 15, 2022
Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled TrialJaclyn A Smith, Michael M Kitt, Alan Bell, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|June 3, 2010
Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteersJeng-Pyng Shaw, Jonathan Cheong, Michael R Goldberg, et al.
Autonomic Neuroscience : Basic & Clinical|August 17, 2021
The discovery and development of gefapixantAnthony P Ford, Michael P Dillon, Michael M Kitt, et al.
The Journal of Antimicrobial Chemotherapy|July 1, 2008
Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjectsShekman L Wong, Steven L Barriere, Michael M Kitt, et al.
Diagnostic Microbiology and Infectious Disease|September 18, 2010
In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studiesKevin M Krause, Steven L Barriere, Michael M Kitt, et al.
Pharmacotherapy|December 25, 2009
Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancinMichael R Goldberg, Shekman L Wong, Jeng-Pyng Shaw, et al.
Pharmacotherapy|July 27, 2010
Single-dose pharmacokinetics and tolerability of telavancin in elderly men and womenMichael R Goldberg, Shekman L Wong, Jeng-Pyng Shaw, et al.
Pharmacotherapy|January 27, 2010
Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjectsShekman L Wong, Michael R Goldberg, Charles H Ballow, et al.
Journal of Clinical Pharmacology|May 16, 2009
Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participantsShekman L Wong, Fritz Sörgel, Martina Kinzig, et al.
American Journal of Surgery|December 20, 2008
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical proceduresSamuel E Wilson, William O'Riordan, Alan Hopkins, et al.
Pulmonary Therapy|August 15, 2022
Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled TrialJaclyn A Smith, Michael M Kitt, Alan Bell, et al.
Pageof 4